Discovery of new indomethacin-based analogs with potentially selective cyclooxygenase-2 inhibition and observed diminishing to PGE2 activities

Loll, 1996, Structure of prostaglandin H2 synthase-1 (COX-1) and its NSAID binding sites, 13 Rimon, 2010, Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1, Proc. Natl. Acad. Sci. U. S. A., 107, 28, 10.1073/pnas.0909765106 Vane, 1994, Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation, Proc. Natl. Acad. Sci. U. S. A., 91, 2046, 10.1073/pnas.91.6.2046 Zidar, 2009, Cyclooxygenase in normal human tissues is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?, J. Cell. Mol. Med., 13, 3753, 10.1111/j.1582-4934.2008.00430.x Kirkby, 2013, Differential COX-2 induction by viral and bacterial PAMPs: consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies, Biochem. Biophys. Res. Commun., 438, 249, 10.1016/j.bbrc.2013.07.006 Smith, 2011, Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis, Chem. Rev., 111, 5821, 10.1021/cr2002992 Zarghi, 2011, Selective COX-2 inhibitors: a review of their structure-activity relationships, Iran. J. Pharm. Res., 10, 655 Peesa, 2016, A perspective review on role of novel NSAID prodrugs in the management of acute inflammation, J. Acute Dis., 5, 364, 10.1016/j.joad.2016.08.002 Rouzer, 2009, Cyclooxygenases: structural and functional insights, J. Lipid Res., 50, S29, 10.1194/jlr.R800042-JLR200 Kurumbail, 1996, Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature, 384, 644, 10.1038/384644a0 Picot, 1994, The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1, Nature, 367, 243, 10.1038/367243a0 Blobaum, 2007, Structural and functional basis of cyclooxygenase inhibition, J. Med. Chem., 50, 1425, 10.1021/jm0613166 Anana, 2006, Synthesis and biological evaluation of linear phenylethynylbenzenesulfonamide regioisomers as cyclooxygenase-1/-2 (COX-1/-2) inhibitors, Bioorg. Med. Chem., 14, 5259, 10.1016/j.bmc.2006.03.050 Gierse, 1996, A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors, J. Biol. Chem., 271, 15810, 10.1074/jbc.271.26.15810 Knights, 2010, Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity, Expert Rev. Clin. Pharmacol., 3, 769, 10.1586/ecp.10.120 Dwivedi, 2015, Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs), Drug Discov. Today, 20, 863, 10.1016/j.drudis.2015.03.004 Moncada, 1977, Human arterial and venous tissues generate prostacyclin (prostaglandin X), a protein inhibitor of platelet aggregation, Lancet, 309, 18, 10.1016/S0140-6736(77)91655-5 Topper, 1996, Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress, Proc. Natl. Acad. Sci. U. S. A., 93, 10417, 10.1073/pnas.93.19.10417 Estevão, 2012, Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening, Eur. J. Med. Chem., 54, 823, 10.1016/j.ejmech.2012.06.040 Black, 1996, From indomethacin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett., 6, 725, 10.1016/0960-894X(96)00100-X Luo, 2005, Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial, Acta Pharmacol. Sin., 26, 926, 10.1111/j.1745-7254.2005.00150.x Carullo, 2017, Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016), MedChemComm, 8, 492, 10.1039/C6MD00569A Walker, 2001, A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors, Biochem. J., 357, 709, 10.1042/bj3570709 Bhattacharyya, 1996, Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1, J. Biol. Chem., 271, 2179, 10.1074/jbc.271.4.2179 Grover, 2015, 2,5-Diaryl-1,3,4-oxadiazoles as selective COX-2 inhibitors and anti-inflammatory agents, RSC Adv., 5, 45535, 10.1039/C5RA01428J Al-Turki, 2017, Design, synthesis, molecular modeling and biological evaluation of novel diaryl heterocyclic analogs as potential selective cyclooxygenase-2 (COX-2) inhibitors, Saudi Pharm. J., 25, 59, 10.1016/j.jsps.2015.07.001 Wey, 2007, Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors, J. Med. Chem., 50, 6367, 10.1021/jm0611861 Weng, 2010, An improved method for the synthesis of carbazolones by palladium/copper-catalyzed intramolecular annulation of N-arylenaminones, Synthesis, 2010, 2926, 10.1055/s-0030-1258141 Mittapalli, 2012, Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor, Bioorg. Med. Chem. Lett., 22, 4955, 10.1016/j.bmcl.2012.06.038 Oikawa, 1977, Selective oxidation of the side chain at C-3 of indoles, J. Org. Chem., 42, 1213, 10.1021/jo00427a024 Wakitani, 1998, Profile of JTE-522 as a human cyclooxygenase-2 inhibitor, Jpn. J. Pharmacol., 78, 365, 10.1254/jjp.78.365 Di Rosa, 1971, Screens for anti-inflammatory drugs, J. Pharm. Pharmacol., 23, 297, 10.1111/j.2042-7158.1971.tb08661.x Abouzeit-Har, 1982, Effect of long term estrogen and lithium treatment on restraint induced gastric erosion in intact and ovariectomized rats, Pharmazie, 37, 593 Rarey, 1996, A fast flexible docking method using an incremental construction algorithm, J. Mol. Biol., 261, 470, 10.1006/jmbi.1996.0477 Vilar, 2008, Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery, Curr. Top. Med. Chem., 8, 1555, 10.2174/156802608786786624